Shyam M Kavuri

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3986121/publications.pdf

Version: 2024-02-01

11 papers	1,228 citations	9 h-index	1199594 12 g-index
13	13	13	3055
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer. Cancer Discovery, 2013, 3, 224-237.	9.4	697
2	Proteogenomic integration reveals therapeutic targets in breast cancer xenografts. Nature Communications, 2017, 8, 14864.	12.8	112
3	The prognostic effects of somatic mutations in ER-positive breast cancer. Nature Communications, 2018, 9, 3476.	12.8	89
4	Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. Cell Reports, 2018, 24, 1434-1444.e7.	6.4	73
5	HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1061-1064.	4.9	70
6	Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer. Cancer Discovery, 2017, 7, 1168-1183.	9.4	58
7	Epigenetic loss of AOX1 expression via EZH2 leads to metabolic deregulations and promotes bladder cancer progression. Oncogene, 2020, 39, 6265-6285.	5.9	52
8	Tobacco-Specific Carcinogens Induce Hypermethylation, DNA Adducts, and DNA Damage in Bladder Cancer. Cancer Prevention Research, 2017, 10, 588-597.	1.5	46
9	Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer. Nature Communications, 2021, 12, 2940.	12.8	14
10	Thioredoxin reductase is a major regulator of metabolism in leukemia cells. Oncogene, 2021, 40, 5236-5246.	5.9	11
11	Abstract P2-13-24: Distinct HER2 allele specific therapeutic response and preclinical efficacy of poziotinib in metastatic ER+ HER2 mutant breast cancer. Cancer Research, 2022, 82, P2-13-24-P2-13-24.	0.9	O